Holen Sie sich die Stockscreener-App
32.38
0.37%
0.12
Handel nachbörslich:
32.38
Schlusskurs vom Vortag:
$32.26
Offen:
$32.21
24-Stunden-Volumen:
818.13K
Relative Volume:
1.36
Marktkapitalisierung:
$1.61B
Einnahmen:
$499.95M
Nettoeinkommen (Verlust:
$-36.36M
KGV:
-42.05
EPS:
-0.77
Netto-Cashflow:
$24.22M
1W Leistung:
+1.82%
1M Leistung:
-17.10%
6M Leistung:
-9.65%
1J Leistung:
-17.00%
1-Tages-Spanne:
$32.00
$33.11
1-Wochen-Bereich:
$30.27
$33.72
52-Wochen-Spanne:
$28.29
$43.18
Atricure Inc Stock (ATRC) Company Profile
Firmenname
Atricure Inc
Sektor
Telefon
513-755-4100
Adresse
7555 INNOVATION WAY, MASON, OH
Compare ATRC vs ISRG, BDX, ALC, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRC
Atricure Inc
|
32.38 | 1.60B | 499.95M | -36.36M | 24.22M | -0.77 |
|
ISRG
Intuitive Surgical Inc
|
499.53 | 177.84B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
182.47 | 51.97B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
83.22 | 40.42B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
47.60 | 39.70B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
RMD
Resmed Inc
|
256.29 | 37.72B | 5.40B | 1.49B | 1.78B | 10.12 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-12-17 | Fortgesetzt | JP Morgan | Overweight |
| 2024-04-23 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-23 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-09-29 | Eingeleitet | UBS | Buy |
| 2021-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-12-18 | Bestätigt | Needham | Buy |
| 2020-11-06 | Bestätigt | Needham | Buy |
| 2020-04-07 | Eingeleitet | Oppenheimer | Outperform |
| 2020-02-06 | Eingeleitet | BTIG Research | Buy |
| 2020-01-24 | Bestätigt | Needham | Buy |
| 2019-08-13 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-04-12 | Eingeleitet | JP Morgan | Overweight |
| 2018-10-04 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Stifel | Buy |
| 2018-06-18 | Bestätigt | Needham | Buy |
| 2018-04-27 | Bestätigt | Needham | Buy |
| 2018-01-16 | Bestätigt | Needham | Buy |
| 2017-11-02 | Bestätigt | Needham | Buy |
| 2017-07-28 | Bestätigt | Needham | Buy |
| 2017-05-30 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-06-30 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2015-10-28 | Bestätigt | Needham | Buy |
| 2015-10-06 | Bestätigt | Canaccord Genuity | Buy |
| 2015-10-06 | Bestätigt | Needham | Buy |
Alle ansehen
Atricure Inc Aktie (ATRC) Neueste Nachrichten
AtriCure, Inc. SEC 10-K Report - TradingView
COR's MWI Animal Health to Merge With Covetrus in $3.5 Billion Deal - Finviz
AtriCure Earnings Call Highlights Growth Amid Headwinds - TipRanks
Demystifying AtriCure: Insights From 6 Analyst Reviews - Benzinga
ATRC: Canaccord Genuity Lowers Price Target, Maintains Buy Ratin - GuruFocus
Needham reiterates Buy on AtriCure stock, keeps $45 target - Investing.com UK
Needham reiterates Buy on AtriCure stock, keeps $45 target By Investing.com - Investing.com Nigeria
UBS Adjusts AtriCure Price Target to $55 From $60, Maintains Buy Rating - marketscreener.com
UBS Maintains 'Buy' Rating on AtriCure (ATRC), Lowers Price Targ - GuruFocus
Citizens Jmp Cuts AtriCure (NASDAQ:ATRC) Price Target to $52.00 - MarketBeat
AtriCure (ATRC) Analyst Maintains Rating, Lowers Price Target to $52 | ATRC Stock News - GuruFocus
AtriCure Delivers 15% Revenue Growth In FY25, Projects 12-14% Growth In FY26 - Nasdaq
This Masimo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
AtriCure, Inc. (NASDAQ:ATRC) Q4 2025 Earnings Call Transcript - Insider Monkey
AtriCure, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
BTIG Research Reaffirms "Buy" Rating for AtriCure (NASDAQ:ATRC) - MarketBeat
Oppenheimer downgrades AtriCure stock rating on competitive concerns - Investing.com UK
Canaccord Genuity lowers AtriCure stock price target on valuation By Investing.com - Investing.com Australia
AtriCure Q4 2025 revenue up 13.1% to USD 140.5M - Medical Buyer
ATRC Downgraded by Oppenheimer to 'Perform' | ATRC Stock News - GuruFocus
Citizens lowers AtriCure stock price target on valuation adjustment By Investing.com - Investing.com South Africa
AtriCure (ATRC): BTIG Reiterates Buy Rating and $54 PT | ATRC St - GuruFocus
AtriCure posts Q4 beats on 13% growth, analysts label it 'undervalued' despite rising competition - MassDevice
Citizens lowers AtriCure stock price target on valuation adjustment - Investing.com
Why AtriCure (ATRC) Is Down 12.9% After Issuing 2026 Profitability Guidance And Revenue Outlook - simplywall.st
AtriCure Inc (ATRC) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
AtriCure reports surprise Q4 profit on strong worldwide revenue growth - AlphaStreet News
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings - sharewise.com
AtriCure Q4 Earnings Call Highlights - MarketBeat
AtriCure (ATRC) Q4 2025 Earnings Call Transcript - The Globe and Mail
AtriCure Inc (NASDAQ:ATRC) Stock Surges on Q4 2025 Earnings Beat and Profitability Milestone - ChartMill
ATRC Projects FY26 Revenue Between $600M and $610M - GuruFocus
AtriCure (ATRC) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
AtriCure: Q4 Earnings Snapshot - kens5.com
AtriCure: Fourth Quarter Earnings Overview - Bitget
AtriCure (NASDAQ:ATRC) Announces Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
AtriCure shares surge as company beats Q4 expectations, issues strong guidance - Investing.com India
Earnings Flash (ATRC) AtriCure, Inc. Reports Q4 Revenue $140.5M, vs. FactSet Est of $139.7M - marketscreener.com
AtriCure Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
AtriCure Q4 Earnings Summary & Key Takeaways - Benzinga
AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results - marketscreener.com
AtriCure Q4 2025 Earnings Call Transcript - MarketBeat
Market Outlook: Is AtriCure Inc undervalued by DCF analysisTrade Risk Summary & Weekly High Momentum Picks - baoquankhu1.vn
AtriCure, Inc. (ATRC) Stock Analysis: Analyst Ratings Suggest A 57.56% Upside Potential - DirectorsTalk Interviews
Smart Money: Should value investors consider AtriCure IncMarket Volume Summary & Consistent Profit Trade Alerts - baoquankhu1.vn
AtriCure earnings on deck as analysts split on growth outlook By Investing.com - Investing.com UK
AtriCure earnings on deck as analysts split on growth outlook - Investing.com Nigeria
Insights into AtriCure's Upcoming Earnings - Benzinga
NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro - Finviz
Quarterly Recap: What are the analyst revisions for SMTCIs AtriCure Inc stock a good investment in YEAR2025 Trading Recap & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Can JPMorgan’s Downgrade Reshape AtriCure’s (ATRC) Competitive Moat In Cardiac Surgery Devices? - Yahoo Finance
Finanzdaten der Atricure Inc-Aktie (ATRC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.74%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):